The results of the Phase III registered clinical trial of CM...

Moomoo AI Oct 11, 2023 16:42

The results of the Phase III registered clinical trial of CM310 showed significant efficacy compared to the placebo group, including improvements in eczema area and severity index, overall investigator assessment score, and itch control and quality of life. This may have a positive impact on the stock price of Conoa-B.

Conoa-B (02162): The top-line data of the CM310 Phase III clinical trial was selected for the 2023 European Dermatology and Venereology Congress poster.

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

4021 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4677Followers

0Following

10KVisitors